鲁抗医药
(600789)
| 流通市值：90.05亿 | | | 总市值：90.05亿 |
| 流通股本：8.99亿 | | | 总股本：8.99亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,624,350,443.62 | 3,153,993,569.88 | 1,673,699,598.01 | 6,233,090,168.38 |
| 营业收入 | 4,624,350,443.62 | 3,153,993,569.88 | 1,673,699,598.01 | 6,233,090,168.38 |
| 二、营业总成本 | 4,428,403,914.86 | 2,972,941,889.51 | 1,603,575,969.64 | 5,966,978,980.46 |
| 营业成本 | 3,620,251,683.58 | 2,444,815,224.77 | 1,327,189,834.53 | 4,739,468,856.52 |
| 税金及附加 | 41,007,726.78 | 27,558,071.89 | 12,414,146.37 | 54,579,240.36 |
| 销售费用 | 321,214,650.79 | 216,345,390.21 | 117,380,480.29 | 568,066,831.42 |
| 管理费用 | 187,113,324.13 | 124,080,869.76 | 63,707,384.01 | 234,127,671.79 |
| 研发费用 | 220,890,477.26 | 138,184,253.75 | 68,836,886.27 | 317,146,873.44 |
| 财务费用 | 37,926,052.32 | 21,958,079.13 | 14,047,238.17 | 53,589,506.93 |
| 其中:利息费用 | 49,263,970.91 | 33,436,229.37 | 16,513,014.71 | 75,379,945.74 |
| 其中:利息收入 | 7,331,679.61 | 5,110,518.76 | 2,318,985.92 | 12,478,792.03 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -71,340 | -71,340 | - | 29,520 |
| 加:投资收益 | -3,110,813.76 | -2,083,662.72 | -1,298,616.79 | -7,590,617.17 |
| 资产处置收益 | 86,544.52 | 54,688.61 | 25,922.24 | 153,424,695.55 |
| 资产减值损失(新) | -49,280,588.26 | -44,919,839.14 | 16,324,221.04 | -66,942,918.06 |
| 信用减值损失(新) | -11,609,396.29 | -19,062,702.1 | -17,889,018.89 | -13,700,137.89 |
| 其他收益 | 58,370,461.57 | 31,954,913.3 | 18,575,566.41 | 104,858,031.51 |
| 四、营业利润 | 190,331,396.54 | 146,923,738.32 | 85,861,702.38 | 436,189,761.86 |
| 加:营业外收入 | 465,294.82 | 186,372.65 | 168,769.63 | 1,683,481.16 |
| 减:营业外支出 | 4,460,610.37 | 4,177,828.25 | 885 | 3,971,830.51 |
| 五、利润总额 | 186,336,080.99 | 142,932,282.72 | 86,029,587.01 | 433,901,412.51 |
| 减:所得税费用 | 39,716,841.04 | 32,284,065.07 | 3,680,616.44 | 25,553,890.68 |
| 六、净利润 | 146,619,239.95 | 110,648,217.65 | 82,348,970.57 | 408,347,521.83 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 146,619,239.95 | 110,648,217.65 | 82,348,970.57 | 408,347,521.83 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 141,196,204.7 | 106,834,976.68 | 78,597,649.89 | 394,615,735.73 |
| 少数股东损益 | 5,423,035.25 | 3,813,240.97 | 3,751,320.68 | 13,731,786.1 |
| 扣除非经常损益后的净利润 | 122,821,840.76 | 100,079,235.02 | 64,656,985.97 | 208,583,495.88 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.16 | 0.12 | 0.09 | 0.44 |
| (二)稀释每股收益 | 0.16 | 0.12 | 0.09 | 0.44 |
| 八、其他综合收益 | -1,986,272.05 | -1,387,189.78 | -1,306,169.17 | -7,452,241.92 |
| 归属于母公司股东的其他综合收益 | -1,986,272.05 | -1,387,189.78 | -1,306,169.17 | -7,452,241.92 |
| 九、综合收益总额 | 144,632,967.9 | 109,261,027.87 | 81,042,801.4 | 400,895,279.91 |
| 归属于母公司股东的综合收益总额 | 139,209,932.65 | 105,447,786.9 | 77,291,480.72 | 387,163,493.81 |
| 归属于少数股东的综合收益总额 | 5,423,035.25 | 3,813,240.97 | 3,751,320.68 | 13,731,786.1 |
| 公告日期 | 2025-10-31 | 2025-08-28 | 2025-04-30 | 2025-03-22 |
| 审计意见(境内) | | | | 标准无保留意见 |